News Archive

On Wednesday, 22 September 2021, 9:00 am–4:30 pm ET, the US Nuclear Regulatory Commission (NRC) and the US Food and Drug Administration (FDA) are hosting a virtual workshop on targeted alpha-emitting radiopharmaceuticals, with a focus on actinium-225. The workshop will feature four sessions with presentations by regulators and industry representatives, each followed by panel discussion of audience questions.

Session topics include:

• Session I–Targeted Alpha Emitters With Focus on Actinium-225 Radiotherapies
• Session II–Novel Radiopharmaceuticals: Standards Development, Product Quality Considerations, Supply and Demand
• Session III–Clinical Considerations for Development of Novel Radiopharmaceuticals
• Session IV–User and Industry Perspective

The workshop will be conducted using Cisco Webex and will also be broadcast live on the NRC's Webcast portal. (Please note that the NRC's Webcast portal will allow you to watch a live broadcast of the workshop, but in order to ask questions of the presenters via chat or audio you must register for and attend the Webex meeting.)

If you would like to submit questions to be considered by the workshop hosts and presenters, please submit them via email any time before the event.

See the FDA's Workshop Page for more information and to register.